Physician profile
Frank H Redd
NPI 1417534983
$2,201.25
in general payments reported to CMS, 2019-2025
21 companies · $685 in 2025
The $685 reported for 2025 was more than what 94% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $340 · 2023: $387 · 2024: $788 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $470.85 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $223.87 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $222.98 | 2024-2025 | Airsupra, Fasenra, Breztri |
| Fisher & Paykel Healthcare INC | $184.44 | 2022-2023 | Fisher & Paykel Healthcare |
| Merck Sharp & Dohme LLC | $169.51 | 2024-2025 | Winrevair, Zerbaxa |
| Glaxosmithkline, LLC. | $148.84 | 2024-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.08 | 2024-2025 | Ofev |
| Vapotherm INC | $91.53 | 2022 | |
| Genzyme Corporation | $87.31 | 2024-2025 | |
| Ceribell, INC. | $75.02 | 2023 | Ceribell Rapid Response Eeg |
| Mallinckrodt Hospital Products INC. | $61.81 | 2024-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $53.59 | 2024 | Dupixent |
| La Jolla Pharmaceutical Company | $49.26 | 2025 | Giapreza |
| Ani Pharmaceuticals, INC. | $42.14 | 2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $35.42 | 2022-2024 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $32.11 | 2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $31.71 | 2023 | Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $30.27 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.41 | 2024-2025 | Glassia |
| United Therapeutics Corporation | $16.18 | 2025 | Tyvaso |
| Insmed, INC. | $13.92 | 2024 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Redd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.